El Orzán : diario independiente: Año XII Número 3306 - 1929 enero 24

Abstract

Patients with hyperlipidemia and chronic kidney disease (CKD) are at high risk for cardiovascular complications, including myocardial infarction, stroke, and arrhythmias. Patients with renal dysfunction should be closely monitored and treated with lipid-lowering therapy to reduce morbidity and mortality. While statins are the primary lipid-lowering therapy recommended in patients with CKD, other antihyperlipidemia medication classes include fibrates, bile acid sequestrants, niacin, ezetimibe, and omega-3 fatty acids. Pharmacists can play a key role in providing recommendations for therapy initiation, medication adjustments in renal dysfunction, and education about medications and adherence